Follows adults hospitalized with a flare-up of COPD over time
Collects health data and samples from adults hospitalized for COPD flare-ups.
Plain-language title generated from the registry record
Registry title: The CATALINA Study
Key facts
- Where
- Ferrara, ItalySee the site
Where in Italy
- University Hospital Of FerraraFerrara, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wim Janssens
- Trial code
- NCT05008081
- Record updated
- 22 May 2026
- Original description
The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.Read full original descriptionShow less
An International Multi-centre Prospective Cohort Study in Patients Hospitalized for an Acute Exacerbation of COPD
The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.
Inclusion: Age 18 years and older; Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test with an FEV1/FVC < 0.7); Current hospitalization with suspicion of an acute exacerbation of COPD (AECOPD); Inclusion within 48 hours post hospital admission; Voluntary written informed consent of the participant or his/her representative obtained prior to any study procedure.
Exclusion: Patients not requiring treatment with systemic corticosteroids, antibiotics or both as a minimum therapy for the index AECOPD; Patients unwilling or unable to comply with study procedures; Patients with a confirmed positive test result for COVID19, or those highly suspected based on clinical examination.